AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01822028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment B
Description: Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
Study NCT01822028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
Study NCT02395705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and paclitaxel
Description: 1. Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~2. Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~3. Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.
Study NCT00684983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO
Study NCT00684983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT00684983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT00684983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib Ditosylate
Description: Given PO
Study NCT00684983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO
Study NCT00684983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00684983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03712098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide 3.0 mg is an injectable medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Liraglutide is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management when combined with a reduced-calorie meal plan and physical activity.
Study NCT00089583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir solution bid
Study NCT00623077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) > 1,000/mm\^2.~Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses.
Study NCT00623077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (>4 yrs of age) or 13.2 mg/kg IV (\< 4 years of age),every 6 hours on Days -8 through -6.
Study NCT00623077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m\^2/day intravenous (IV) over 1 hour for 5 days.
Study NCT00623077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day intravenous (IV) over 1 hour on for 5 days.
Study NCT00623077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m\^2 intravenous (IV) over 30 min on Days -5 through -4.
Study NCT00623077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m\^2 intravenously (IV) over 2 hrs on Days -3 through -2.
Study NCT00623077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
Study NCT00623077 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy~/minute (instantaneous dose rate).
Study NCT00623077 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow irradiation
Description: TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9.
Study NCT03712098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo is an inactive substance that is designed to look like liraglutide but contains no medication.
Study NCT00623077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day divided in every 6 hrs dosing for 5 days.
Study NCT03712098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: All participants receive manual-based counseling from a trained smoking cessation counselor. The counseling sessions are designed to enhance awareness of the harmful effects of smoking, assist the participant in developing skills to quit, and avoid relapse.
Study NCT03712098 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: All participants receive manual-based counseling from a trained smoking cessation counselor. The counseling sessions are designed to enhance awareness of the harmful effects of smoking, assist the participant in developing skills to quit, and avoid relapse.
Study NCT00623077 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole lung radiation
Description: At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
Study NCT01609153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Coated tablet 5-20 mg milligram(s) per day for 16 weeks
Study NCT01609153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: 200-800 mg milligram(s)per day for 16 weeks
Study NCT02588781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
Study NCT03504085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga: Active Hatha
Description: Classical Hatha yoga with influences from Viniyoga and Iyengar yoga. Both Viniyoga and Iyengar yoga styles emphasize modifications and adaptations including the use of props such as straps and blocks in order to minimize the risk of injury and make the poses accessible to people with health problems and limitations
Study NCT01609153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine and Amisulpride
Description: Zyprexa:~Coated tablet 5-20 mg milligram(s) per day for 16 weeks~Amisulpride:~Coated tablet 200-800 mg milligram(s)per day for 16 weeks
Study NCT04153513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanolin
Description: Lanolin will be applied by hand in a thin layer to the nipple and areola after every breast feed (approximately every 2 to 3 hours) for a maximum of 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
Study NCT04153513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mother's milk
Description: After each breast feed (approximately every 2 to 3 hours), a few drops of breast milk will be applyed to the nipple and areola by hand and allow them to air dry. The treatment will last for up to 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
Study NCT03016013 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus MTX
Description: The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.
Study NCT03016013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160 mg plus MTX
Description: The trial was divided into two groups: (1) placebo + MTX; (2) telitacicept 160 mg + MTX. MTX was used as the basic treatment, the dose of MTX was stable during the trial, and could not be adjusted. Telitacicept or placebo was administered once a week for the first 24 weeks. Beginning at week 24, subjects in the placebo group will enter the RC-18 treatment group. All subjects received RC-18 treatment once a week from week 24 to week 48.
Study NCT03504085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga: Restorative
Description: Restorative Yoga is a slow-paced yoga style that emphasizes relaxation and includes very little movement.
Study NCT02779400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self testing INR device
Description: the procedure involves a series of repeated measurements of INR with the studied device
Study NCT03815903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction chemotherapy
Description: 3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2
Study NCT03815903 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
Study NCT04581824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered through a 30 minute infusion at a dose of 500 milligrams (mg) intravenously (IV) every 3 weeks (Q3W) up to a maximum of 35 cycles (each cycle of 21 days).
Study NCT03815903 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
Study NCT03867071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: recombinant erythropoietin injection
Description: Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).
Study NCT03867071 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: Intravenous injection 0,9% saline solution.
Study NCT02704091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smecta
Study NCT04581824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered through a 30 minute infusion at a dose of 200 mg Q3W up to a maximum of 35 cycles (each cycle of 21 days).
Study NCT02704091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Smecta placebo
Study NCT02483195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% Minoxidil
Description: This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
Study NCT02483195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200mg Spironolactone
Description: This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
Study NCT02483195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5mg Finasteride
Description: This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
Study NCT02483195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
Study NCT04581824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.
Study NCT04581824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Pemetrexed will be administered at 500 milligram per meter square (mg/m\^2 ) IV through a 10 minute IV infusion Q3W, up to a maximum of 35 cycles (each cycle of 21 days).~Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.~Carboplatin will also be administered at area under the concentration time curve 5 milligram/milliliters/minute (mg/mL/min) (maximum dose: 750 mg) through a 15 to 60 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine formulation 1
Description: Pharmaceutical form:liquid Route of administration: intramuscular
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine formulation 2
Description: Pharmaceutical form:liquid Route of administration: intramuscular
Study NCT03204786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Nasal Spray
Study NCT03204786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Nasal Spray
Study NCT03360786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific intervention
Description: Series of progressive exercises targeted at balance, adaptation, dividing attention, head on neck control, visual + education on concussion identification and concussion education
Study NCT03360786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Education on concussion and concussion identification in addition to typical cardiovascular warmups
Study NCT00983788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: 3 x 200 mg/ day
Study NCT00983788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03362307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Level Laser and Light-Emitting Diodes
Description: Combination of Low-Level Laser and Light-Emitting Diodes were used after dental implant placement for enhancement of stability
Study NCT03362307 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low-Level Laser and Light-Emitting Diodes
Description: Combination of Low-Level Laser and Light-Emitting Diodes were used after dental implant placement for enhancement of stability
Study NCT03362307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement
Description: A dental implant with 4.8X 10 mm (Zimmer, USA) size was placed at the posterior of the mandible
Study NCT03362307 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dental implant placement
Description: A dental implant with 4.8X 10 mm (Zimmer, USA) size was placed at the posterior of the mandible
Study NCT01469117 — intervention group
Intervention type: OTHER
Intervention: enteral formula
Description: Complete feeding of study enteral formula, route and regimen prescribed by the physician
Study NCT03551340 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastro-intestinal panel by PCR
Description: The study will evaluate the change in medical management with the replacement of traditional stool investigations (microscopy and culture) by the new gastrointestinal multiplex PCR panels
Study NCT04957498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help for Family Based Treatment
Description: A online website provided to parents containing information learned in Family Based Treatment and up to 12 coaching sessions with a therapist.
Study NCT04957498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Treatment
Description: Standard Family Based Treatment provided for up to 15 sessions.
Study NCT04372355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WF10
Description: WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.
Study NCT03898583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microarray patch A
Description: Microarray patch
Study NCT03898583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microarray patch B
Description: Microarray patch
Study NCT03898583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microarray patch vehicle
Study NCT03898583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet
Description: Daivobet Gel
Study NCT03634046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy
Description: The same as the descriptions in experimental group.
Study NCT03634046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: The same as the descriptions in active comparator group.
Study NCT03634046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: The same as the descriptions in active comparator group.
Study NCT02383719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oro-nasal Mask
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine formulation 3
Description: Pharmaceutical form:liquid Route of administration: intramuscular
Study NCT01899144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax
Description: Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
Study NCT02807805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT02807805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: Given PO
Study NCT02807805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02563834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiapalmitate tracer
Description: Radiolabeled tracer infusion; occurs in all treatment arms
Study NCT01899144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAir HFA
Description: ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
Study NCT01899144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Virus Vaccine Live
Description: Pharmaceutical form:liquid Route of administration: subcutaneous
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella Virus Vaccine Live
Description: Pharmaceutical form:liquid Route of administration: subcutaneous
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live
Description: Pharmaceutical form:liquid Route of administration: subcutaneous
Study NCT02563834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline infusion for control
Study NCT02563834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin infusion for insulin/glucose clamp procedure
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live
Description: Pharmaceutical form:liquid Route of administration: subcutaneous
Study NCT04398706 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Description: Pharmaceutical form:liquid Route of administration: intramuscular